कंपनी का अवलोकन
Actinium Pharmaceuticals, Inc. (ATNM) is a biotechnology enterprise focused on the development of antibody radiation conjugates and targeted radiotherapies designed to improve clinical outcomes for patients who have exhausted existing oncology treatment options. Operating within the Healthcare sector and the specific Biotechnology industry, the company leverages advanced scientific research to create novel therapies for myeloid malignancies and other conditions where standard therapies have failed. The organization maintains a lean operational structure with a workforce comprising 25 employees, which is typical for early-stage clinical development firms concentrating resources on specific product candidates. With a market capitalization of $35.77M and trailing twelve-month revenue of $90,000, the company's financial scale indicates a pre-revenue or very early commercialization stage where capital efficiency is critical for advancing two clinical stage product candidates, including Actimab-A.
वित्तीय स्वास्थ्य
The company reported trailing twelve-month revenue of $90,000 against a net income of $-33,887,000 and an EBITDA of $-36,064,000, revealing a significant structural gap where operating costs and research expenditures vastly exceed current sales income. This massive deficit between minimal revenue and substantial net losses highlights the heavy investment required in clinical trials and drug development typical for biotechnology firms before reaching profitability. Free cash flow stands at $-12,849,375, indicating that the company is consuming cash reserves to fund operations and development rather than generating surplus liquidity from its current business activities. Margin analysis shows a Gross Margin of 100.0%, suggesting no cost of goods sold in the current accounting period, while the Operating Margin of -40274.4% and Profit Margin of 0.0% reflect the extreme burn rate inherent in the current development phase. The balance sheet holds $48.00M in cash against $1.69M in debt, resulting in a Debt to Equity ratio of 21.62, which suggests a capital structure heavily reliant on equity financing rather than debt leverage despite the negative earnings. A Current Ratio of 6.20 demonstrates robust short-term liquidity, as current assets are more than six times current liabilities, providing ample buffer to sustain operations during the long development cycle. Return on Equity is -167.0% and Return on Assets is -35.2%, metrics that mathematically reflect the dilutive impact of losses on shareholder value and asset efficiency during the pre-commercialization stage.
मूल्यांकन आकलन
The valuation metrics present a complex picture for a loss-making biotechnology entity, with a Trailing P/E (TTM) listed as N/A due to the absence of positive earnings, while the Forward P/E is recorded at -2.02, indicating an expected continued loss in the near future. The Price to Book ratio stands at 4.54, suggesting the market values the company's equity at a significant premium over its net asset value, likely reflecting the potential intrinsic value of its intellectual property and pipeline assets. The Price to Sales ratio is exceptionally high at 397.42, and the EV/EBITDA is 0.30, both of which are alternative valuation measures that often inflate for early-stage companies as they attempt to normalize valuation multiples before positive cash flow returns. The stock's 52-week trading range spans from a low of $0.95 to a high of $1.95, meaning the current price sits within this volatility band and is subject to significant swings relative to the company's lack of historical earnings data. The Beta value of -0.21 is a unique statistical anomaly indicating an inverse relationship to the broader market, where the stock tends to move in the opposite direction of the market index, suggesting distinct risk factors unrelated to general market sentiment.
Growth & Income
Growth metrics for the company are currently listed as N/A for both Revenue Growth (YoY) and Earnings Growth (YoY), which implies that the business is not yet in a stable growth phase where year-over-year comparisons yield meaningful statistical data for investors. The company does not pay a dividend, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, which means all available earnings are theoretically retained or, more accurately, the company relies entirely on external capital to fund operations. Consequently, the firm reinvests its limited resources, specifically its $48.00M cash reserve, into advancing its clinical stage product candidates rather than distributing income to shareholders. The overall growth and income profile is characterized by high risk and zero current income distribution, relying on future clinical success and regulatory approval to transition into a revenue-generating and potentially profitable entity.